secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001404644-26-000030
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene appoints Christy Shafer as CCO, Christine Mikail to Board
-------------------------------------------------------------------

- Christy Shafer joins as CCO; previously SVP/GM at Avidity Biosciences and CCO at Marinus Pharmaceuticals.
- Shafer will lead commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome.
- Christine Mikail, President and CFO, appointed to Board as Class II director through 2028 annual meeting.
- Mikail brings expertise in strategy, finance, and corporate development; no additional compensation for board role.
- Appointments position Neurogene for next phase of growth as it advances NGN-401 toward potential launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000030/0001404644-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000030/ngne-20260420.htm
  HTML page:      https://secwatch.observer/filing/0001404644-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer